Informação sobre produto
Nome:RG 13022
Marca:Biosynth
Descrição:RG 13022 is a tyrosine kinase inhibitor that blocks the activity of protein tyrosine kinases and prevents the activation of proteins downstream in the cell signaling pathway. RG 13022 has been shown to inhibit cell proliferation, induce apoptosis, and significantly decrease tumor volume in a model system. It also inhibits the growth of subcutaneous tumors in mice by blocking the mitogenic effects of epidermal growth factor receptor (EGFR) and other receptor activities. RG 13022 has demonstrated cytotoxicity against cancer cells lines derived from human carcinoma, including squamous carcinoma.br>
RG 13022 is orally bioavailable and has shown no significant toxicity or side effects in animal studies. It can be used for treatment of cancer as well as for prevention of relapse after chemotherapy.br>
RG 13022 is orally bioavailable and has shown no significant toxicity or side effects in animal studies. It can be used for treatment of cancer as well as for prevention of relapse after chemotherapy.br>
Aviso:Os nossos productos estão destinados exclusivamente para uso em laboratório. Para qualquer outra aplicação, por favor entre em contacto.
Propriedades químicas
Peso molecular:266.29 g/mol
Fórmula:C16H14N2O2
Pureza:Min. 95%